Literature DB >> 26818876

Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery.

Sachin Gharse, Jennifer Fiegel1.   

Abstract

The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 µm are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm(3)), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.

Entities:  

Mesh:

Year:  2016        PMID: 26818876      PMCID: PMC4978149          DOI: 10.2174/1381612822666160128145356

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  61 in total

Review 1.  Drug-resistant and multidrug-resistant tubercle bacilli.

Authors:  B Petrini; S Hoffner
Journal:  Int J Antimicrob Agents       Date:  1999-10       Impact factor: 5.283

Review 2.  Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.

Authors:  Fakhrul Ahsan; Isabel P Rivas; Mansoor A Khan; Ana I Torres Suarez
Journal:  J Control Release       Date:  2002-02-19       Impact factor: 9.776

3.  Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery.

Authors:  Jangwook Lee; Yu Jin Oh; Sang Kyung Lee; Kuen Yong Lee
Journal:  J Control Release       Date:  2010-05-26       Impact factor: 9.776

Review 4.  Inhalation therapy: an historical review.

Authors:  Mark Sanders
Journal:  Prim Care Respir J       Date:  2007-04

5.  PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.

Authors:  Brijeshkumar Patel; Vivek Gupta; Fakhrul Ahsan
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

6.  Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.

Authors:  A I Bot; T E Tarara; D J Smith; S R Bot; C M Woods; J G Weers
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

Review 7.  The resumption of consumption -- a review on tuberculosis.

Authors:  Rodrigo Gay Ducati; Antonio Ruffino-Netto; Luiz Augusto Basso; Diógenes Santiago Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  2006-11       Impact factor: 2.743

8.  Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats.

Authors:  Cynthia Bosquillon; Véronique Préat; Rita Vanbever
Journal:  J Control Release       Date:  2004-04-28       Impact factor: 9.776

9.  Development of highly porous large PLGA microparticles for pulmonary drug delivery.

Authors:  Yan Yang; Nimisha Bajaj; Peisheng Xu; Kimberly Ohn; Michael D Tsifansky; Yoon Yeo
Journal:  Biomaterials       Date:  2009-01-08       Impact factor: 12.479

10.  Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.

Authors:  Francesca Ungaro; Roberta d'Emmanuele di Villa Bianca; Concetta Giovino; Agnese Miro; Raffaella Sorrentino; Fabiana Quaglia; Maria Immacolata La Rotonda
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

View more
  6 in total

Review 1.  The emergence of nanoporous materials in lung cancer therapy.

Authors:  Deepika Radhakrishnan; Shan Mohanan; Goeun Choi; Jin-Ho Choy; Steffi Tiburcius; Hoang Trung Trinh; Shankar Bolan; Nikki Verrills; Pradeep Tanwar; Ajay Karakoti; Ajayan Vinu
Journal:  Sci Technol Adv Mater       Date:  2022-07-20       Impact factor: 7.821

2.  Dry Powder Formulation of Simvastatin Nanoparticles for Potential Application in Pulmonary Arterial Hypertension.

Authors:  Shalaleh Zendehdel Baher; Shadi Yaqoubi; Kofi Asare-Addo; Hamed Hamishehkar; Ali Nokhodchi
Journal:  Pharmaceutics       Date:  2022-04-20       Impact factor: 6.525

3.  Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.

Authors:  Cristina Fernández-Paz; Estefanía Fernández-Paz; Pablo Salcedo-Abraira; Sara Rojas; Sheila Barrios-Esteban; Noemi Csaba; Patricia Horcajada; Carmen Remuñán-López
Journal:  Molecules       Date:  2021-10-23       Impact factor: 4.411

4.  Combined computational and experimental studies of molecular interactions of albuterol sulfate with bovine serum albumin for pulmonary drug nanoparticles.

Authors:  Shao-Hui Lin; Wei Cui; Gui-Ling Wang; Shuai Meng; Ying-Chun Liu; Hong-Wei Jin; Liang-Ren Zhang; Ying Xie
Journal:  Drug Des Devel Ther       Date:  2016-09-15       Impact factor: 4.162

Review 5.  COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.

Authors:  Valamla Bhavana; Pradip Thakor; Shashi Bala Singh; Neelesh Kumar Mehra
Journal:  Life Sci       Date:  2020-08-23       Impact factor: 5.037

Review 6.  PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application.

Authors:  Yue Su; Bolun Zhang; Ruowei Sun; Wenfang Liu; Qubo Zhu; Xun Zhang; Rongrong Wang; Chuanpin Chen
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.